Cardiff Oncology
CRDF
117 hedge funds and large institutions have $39.7M invested in Cardiff Oncology in 2026 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 37 reducing their positions, and 14 closing their positions.
908% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $118K
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
6% more funds holding
Funds holding: 110 → 117 (+7)
4.47% less ownership
Funds ownership: 40.45% → 35.98% (-4.5%)
19% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 37
48% less capital invested
Capital invested by funds: $76.6M → $39.7M (-$36.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$643K |
| 2 |
Renaissance Technologies
New York
|
+$208K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$157K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$145K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$2.11M |
| 2 |
Two Sigma Investments
New York
|
-$1.06M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$968K |
| 4 |
Goldman Sachs
New York
|
-$512K |
| 5 |
ACA
Acorn Capital Advisors
New York
|
-$411K |
CRDF Hedge Fund Activity: Q1 2026 in Review
117 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2026, worth a combined $39.7M — down 48% from $76.6M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CRDF positions and 14 closed out — a net gain of 9 holders — while 30 added to existing stakes and 37 trimmed.
The largest buyer was UBS Group, adding an estimated $643K. The largest seller was William Blair & Company, cutting an estimated $2.11M.
- 117 institutional investors held Cardiff Oncology (CRDF) as of Q1 2026, up from 110 in Q4 2025.
- Funds reported $39.7M of Cardiff Oncology stock for Q1 2026, down 48% quarter-over-quarter.
- 23 funds opened new Cardiff Oncology positions in Q1 2026 and 14 closed out, a net change of +9 holders.
- The largest Cardiff Oncology buyer in Q1 2026 was UBS Group, an estimated $643K added.
- The largest Cardiff Oncology seller in Q1 2026 was William Blair & Company, an estimated $2.11M sold.
Based on aggregated 13F filings for Q1 2026.